08:00 , Jan 27, 2014 |  BioCentury  |  Finance

Taiwan's biotech boom

As Taiwan's traditional growth sectors in IT, electronics and manufacturing have cooled, local investors have begun to look for new places to invest. Many are betting biotech is the next big thing. Indeed, the last quarter...
07:00 , Aug 12, 2013 |  BioCentury  |  Finance

Abiding no more

Abiding no more Unable to raise venture money when it spun out of service play Epitomics Inc. in 2010, Apexigen Inc. was able to work for three years using $2 million in seed funding plus partnership...
07:00 , Jul 2, 2012 |  BioCentury  |  Finance

2Q Stock Wrap-Up: Magic in mid-caps

Mid-caps performed best last quarter, with four companies gaining more than 50%. Other segments largely held on to their 1Q gains, except for companies valued below $200 million, which fell 15% in the quarter and...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Company News

Abcam, Epitomics deal

Abcam completed its tender offer for Epitomics, acquiring 36.2 million shares (99.8%). Abcam said it will initiate a compulsorily acquisition procedure to acquire all remaining shares of Epitomics (see BioCentury, March 12). Abcam plc (LSE:ABC),...
07:00 , Mar 12, 2012 |  BC Week In Review  |  Company News

Abcam, Epitomics deal

Protein research tool supplier Abcam will acquire Epitomics in a stock and cash deal valued at $155 million, net of Epitomics' $15 million in cash. The purchase price includes $77.5 million in cash and $77.5...
07:00 , Mar 12, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) was off $1.08 to $16.01 last week after FDA said an NDA for lomitapide to treat homozygous familial hypercholesterolemia (HoFH) would receive a standard review, instead of Priority Review as...
01:25 , Mar 6, 2012 |  BC Extra  |  Company News

Abcam to acquire Epitomics

Protein research tool supplier Abcam plc (LSE:ABC) will acquire Epitomics Inc. (Burlingame, Calif.) in a stock and cash deal valued at $155 million, net of Epitomics' $15 million in cash. The purchase price includes $77.5...
07:00 , Aug 1, 2011 |  BC Week In Review  |  Company News

Epitomics sales and marketing update

Epitomics launched 23 antibodies for cancer research worldwide that were developed through a partnership with the National Cancer Institute's Center for Cancer Research under a 2008 deal. The antibodies were developed using Epitomics' Rabbit Monoclonal...
07:00 , Jun 6, 2011 |  BC Week In Review  |  Company News

Epitomics, Bayer deal

Epitomics will use its RabMAb technology to produce antibodies for use in Bayer's drug target identification and validation. Details were not disclosed. RabMAb utilizes hybridomas created by fusing B cells from an immunized rabbit with...
07:00 , Mar 28, 2011 |  BC Week In Review  |  Company News

Dako, Epitomics deal

The companies partnered to develop rabbit mAbs for cancer companion diagnostics. Financial terms were not disclosed. Dako A/S, Glostrup, Denmark   Epitomics Inc., Burlingame, Calif.   Business: Diagnostic   ...